FEM
  • Home
  • About FEM
  • Team
  • Psychedelics 101
    • Ketamine
    • MDMA
    • Psilocybin
    • LSD
    • Cannabis
  • Research & Academia
  • Aerospace and Science
  • Events & Media
  • Gallery
  • Contact Us
  • More
    • Home
    • About FEM
    • Team
    • Psychedelics 101
      • Ketamine
      • MDMA
      • Psilocybin
      • LSD
      • Cannabis
    • Research & Academia
    • Aerospace and Science
    • Events & Media
    • Gallery
    • Contact Us
FEM
  • Home
  • About FEM
  • Team
  • Psychedelics 101
    • Ketamine
    • MDMA
    • Psilocybin
    • LSD
    • Cannabis
  • Research & Academia
  • Aerospace and Science
  • Events & Media
  • Gallery
  • Contact Us

Highlights in Research

FDA Approvals

Treating Fibromyalgia

Treating Fibromyalgia

 FDA approves 10 cities across the USA to administer MDMA in a Phase 3 clinical trial. 

Read More

Treating Fibromyalgia

Treating Fibromyalgia

Treating Fibromyalgia

 Imperial College of London Centre for Psychedelic Research is studying the effects of Psilocybin and treating Fibromyalgia. 

Read More

Theory on Gut Health

Treating Fibromyalgia

Theory on Gut Health

 A theory is that low doses of psychedelics induce their effects via alterations in the gut microbiome and related pathways to the brain. 

Read More

Psychedelic Use

Reduced Suicidal Ideations

Theory on Gut Health

 Lifetime use of naturalistic psychedelics was associated with a 60% reduced hazard for suicidality. 

Read More

Reduced Suicidal Ideations

Reduced Suicidal Ideations

Reduced Suicidal Ideations

 Psychedelic use resulted in a 14% reduced likelihood of suicidal thinking within the past year, a 29% reduced likelihood of suicide planning within the past year, and a 36% reduced likelihood of attempting suicide within the past year. 

Read More

Clinical Trials

Reduced Suicidal Ideations

Reduced Suicidal Ideations

 97 clinical trials recruiting volunteer participants. 

Read More

Supporting Organizations

Multidisciplinary Association for Psychedelic Studies (MAPS)

The Center for Psychedelic Medicine in NYU Langone's Dept. of Psychiatry

The Center for Psychedelic Medicine in NYU Langone's Dept. of Psychiatry

Learn More

The Center for Psychedelic Medicine in NYU Langone's Dept. of Psychiatry

The Center for Psychedelic Medicine in NYU Langone's Dept. of Psychiatry

The Center for Psychedelic Medicine in NYU Langone's Dept. of Psychiatry

Learn More

The Johns Hopkins Psychedelic Research Unit

The Center for Psychedelic Medicine in NYU Langone's Dept. of Psychiatry

Massachusetts General Hospital Neuroscience of Psychedelics Atai Fellowship

Learn More

Massachusetts General Hospital Neuroscience of Psychedelics Atai Fellowship

Translational Neuroscience center at University of California San Francisco

Massachusetts General Hospital Neuroscience of Psychedelics Atai Fellowship

Learn More

Yale University Program for Psychedelic Science.

Translational Neuroscience center at University of California San Francisco

Translational Neuroscience center at University of California San Francisco

Learn More

Translational Neuroscience center at University of California San Francisco

Translational Neuroscience center at University of California San Francisco

Translational Neuroscience center at University of California San Francisco

Learn More

Center for Psychedelic Drug Research & Education at The Ohio State University

The Center for Psychedelic Psychotherapy and Trauma Research | Icahan School of Medicine at Mount Si

Center for Psychedelic Drug Research & Education at The Ohio State University

Learn More

UW–Madison Transdisciplinary Center for Research in Psychoactive Substances.

The Center for Psychedelic Psychotherapy and Trauma Research | Icahan School of Medicine at Mount Si

Center for Psychedelic Drug Research & Education at The Ohio State University

Learn More

The Center for Psychedelic Psychotherapy and Trauma Research | Icahan School of Medicine at Mount Si

The Center for Psychedelic Psychotherapy and Trauma Research | Icahan School of Medicine at Mount Si

The Center for Psychedelic Psychotherapy and Trauma Research | Icahan School of Medicine at Mount Si

Learn More

Medicinal Research

Additional Information

  • Anthropological research indicates that these mushrooms have been used by several indigenous cultures and societies for millennia.  https://psychiatry.arizona.edu/news/psilocybin-and-ocd
  • 67% of participants in the MDMA group no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. https://maps.org/news/media/the-new-york-times-a-psychedelic-drug-passes-big-test-for-ptsd-treatment/ 
  • There is evidence that, under the right circumstances, psychedelic drugs such as psilocybin can rapidly alleviate core symptoms of diverse psychiatric illnesses, for example, depression, even in severe cases which are resistant to current treatments.  https://www.psypost.org/2022/04/new-research-sheds-light-on-how-psilocybin-influences-sleeping-patterns-62850
  • Diagnoses that psychedelics are currently being tested to treat include: Alcohol Use Disorder, Parkinson's', Autism, Depression, Bipolar, Substance Use Disorder, Fibromyalgia, Migraine Headaches, Anxiety, PTSD, OCD, Binge Eating Disorder, Pancreatic Cancer, and Alzheimer's. https://psychedelicspotlight.com/psychedelic-clinical-trials-recruiting-volunteers/
  • Psychedelics regulate inflammatory pathways via novel mechanisms and may represent a new and exciting treatment strategy for several inflammatory disorders. https://pubmed.ncbi.nlm.nih.gov/30102081/ 

Investment & legal

Investments

Investments

Investments

  • ‘Shark Tank’ host Kevin O’Leary: Psychedelic drugs ‘far exceed’ cannabis investment potential. https://www.cnbc.com/2021/05/11/kevin-oleary-psychedelic-drugs-far-exceed-cannabis-potential.html
  • Peter Thiel has led a $125 million funding round into a start-up aiming to make psychedelic drugs to treat mental health disorders. https://www.cnbc.com/2020/11/23/peter-thiel-backs-psychedelics-startup-atai.html
  • MindMed (Nasdaq: MNMD), Atai Life Sciences (Nasdaq: ATAI), and Compass Pathways (Nasdaq: CMPS) are three of the largest and most significant psychedelic companies. https://psychedelicspotlight.com/psychedelic-stock-analysis-mindmed-atai-life-sciences-compass-pathways/

Legal

Investments

Investments

  • Summer of 2020, Health Canada granted exemptions under Section 56 of the Controlled Drugs and Substances Act to provide access to cancer patients for end-of-life care. https://www.lexpert.ca/legal-insights/canadas-psychedelic-future-a-guide-to-the-evolving-legal-and-regulatory-landscape-and-whats-next/355954
  • Oregon: Measure 109 and Measure 110, the ballot initiative that expands access to substance abuse treatment and decriminalizes small amounts of psychoactive substances. https://lwvpdx.org/wp-content/uploads/2020/10/MEASURE-109.pdf
  • New Jersey: S3256 - Reclassifies possession of psilocybin as a disorderly person's offense. https://pub.njleg.gov/bills/2020/S3500/3256_I1.PDF
  • A New Database Seeks to Prevent “Bad” Psychedelic Patents. https://www.lucid.news/new-database-prevent-bad-psychedelic-patents/

Books to Explore

Copyright © 2025 FEM - All Rights Reserved.

  • Home
  • About FEM
  • Team
  • Research & Academia
  • Aerospace and Science
  • Events & Media
  • Gallery
  • Contact Us

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept